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Abstract
Background: Primary small cell carcinoma (SCC) of the esophagus is a rare and aggressive tumor
with poor prognosis. In this study, we report the clinicopathological characteristics of 21 cases of
small cell carcinoma of the esophagus treated at the Cancer Center of Sun Yat-Sen University, with
particular focus on the histologic and immunohistochemical findings.
Methods:  Twenty-one patient records were reviewed including presenting symptoms,
demographics, disease stage, treatment, and follow-up. Histologic features were observed and
immunohistochemical detection of cytokeratin (CK), epithelial membrane antigen (EMA), neuron
specific enolase (NSE), synaptophysin (Syn), chromogranin A (CgA), neuronal cell adhesion
molecules (CD56), thyroid transcriptional factor-1 (TTF-1) and S100 protein (S100) was
performed.
Results: The median age of patients in the study was 56 years, with a male-to-female ratio of 3.2:1.
Histologically, there were 19 "homogenous" SCC esophageal samples and 2 samples comprised of
SCC and well-differentiated squamous cell carcinoma. The percentages of SCC samples with
positive immunoreactivity were Syn 95.2%, CD56 76.2%, TTF-1 71.4%, NSE 61.9%, CgA 61.9%, CK
57.1%, EMA 61.9%, and S100 19.0%, respectively. The median patient survival time was 18.3 months
after diagnosis. The 2-year survival rate was 28.6%.
Conclusion: Our study suggests that esophageal SCC has similar histology to SCC that arises in
the lung compartment, and Chinese patients have a poor prognosis. Higher proportion of positive
labeling of Syn, CD56, CgA, NSE, and TTF-1 in esophageal SCC implicate that they are valuably
applied in differential diagnosis of the malignancy.
Background
Primary small cell carcinoma (SCC) of the esophagus is a
relatively rare malignancy, accounting for 0.05 – 4% of all
esophageal malignancies [1]. It is a highly aggressive
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tumor associated with a poor prognosis, similar to SCC
that arises in the lung [2] and other extrapulmonary
organs, including breast [3], ovary [4], uterine cervix [5],
liver [6], salivary gland [7], stomach [8], colon [9], pros-
tate [10], urinary bladder [11], and kidney [12]. Histolog-
ically, SCC is characterized by neuroendocrine-like
architectural patterns, including nested and trabecular
growth with common features including peripheral pal-
isading and rosette formation in the tumors [2-12]. Some
SCC cases include carcinomas such as squamous cell car-
cinoma and adenocarcinoma [2]. Analogous to small cell
lung cancer, diagnosis of esophageal SCC is aided by
immunohistochemical staining for common neuroendo-
crine markers, including Syn, CgA and NSE. Recently,
CD56 (neuronal cell adhesion molecule) and TTF-1 (Thy-
roid Transcriptional Factor-1) were also reported to be
high positivity in small cell carcinoma arising in different
organs and thought to be useful markers for diagnosis of
the tumor.
A total of 4050 patients with esophageal malignancies
were seen at the Cancer Center of Sun Yat-Sen University
during the period between 1989 to 2005, and 21 of these
cases were diagnosed as esophageal SCC. The conclusions
of this study focus on the histologic and immunohisto-
chemical findings of these 21 cases.
Methods
Between 1989 and 2005, a total of 4050 Chinese patients
with esophageal carcinoma were seen in the Department
of Thoracic Surgery Unit of the Cancer Center of Sun Yat-
Sen University. Of these patients, a total of 21 cases were
diagnosed as small cell carcinoma of the esophagus, using
histological criteria for esophageal small cell carcinoma
[13] and pulmonary small cell carcinoma [14] prepared
by the World Health Organization. The clinical, patho-
logic, and radiographic records were reviewed. The
reported data includes gender, age, initial symptoms and
duration, pathological examination, lymph node metas-
tases, upper gastrointestinal barium studies, endoscopic
biopsy, Doppler ultrasound of the abdomen, chest radi-
ography or computed tomography scan of the thorax,
treatment, and follow-up. All of the human specimens in
the study were approved by the Independent Ethics Com-
mittee of the Cancer Center of Sun Yat-Sen University.
For immunohistochemistry studies, a labeled-streptavi-
din-biotin (LAB-SA) method was performed with Histo-
stain®-Plus Bulk Kit Zymed®  2nd  generation LAB-SA
detection system (CAT. NO. 85-9043, Zymed Laborato-
ries, CA). Immunological markers included pancytokera-
tin (CK; mouse monoclonal antibody; Clone:AE1/AE3;
Cat No. 18-0132; Zymed, CA), epithelial membrane anti-
gen (EMA; mouse monoclonal antibody; Clone:MC-5;
Cat No. MU182-UC; BioGenex, CA), neuron specific eno-
lase (NSE; mouse monoclonal antibody; Clone:NSE-1G4;
Cat No. 18-01963; Zymed, CA), synaptophysin (Syn;
mouse monoclonal antibody; Clone:snp88; Cat No.
MU363-UC; BioGenex, CA), chromogranin A (CgA;
mouse monoclonal antibody; Clone:LK2H10; Cat No.
MU126-UC; BioGenex, CA), neuronal cell adhesion mol-
ecule (CD56; mouse monoclonal antibody;
Clone:123C3; Cat No.18-0152; Zymed, CA), Thyroid
Transcriptional Factor-1 (TTF-1; mouse monoclonal anti-
body; Clone:8G7G3/1; Cat No.18-0221; Zymed, CA) and
S100 protein (S100; mouse monoclonal antibody;
Clone:4C4.9; Cat No. Z2055; Zeta, CA). All the primary
antibodies were ready to use without dilution. Each paraf-
fin-embedded tissue section (4 μm in thickness) was
deparaffinized, hydrated, and incubated in 3% H2O2 and
microwaved for 3 minutes to block endogenous peroxi-
dase activity. The tissue sections were subjected to antigen
retrieval by microwaving in 10 mM citrate buffer for 30
min. The sections were incubated with serum blocking
solution (Reagent A) for 10 minutes to block nonspecific
binding and then with the primary antibodies in moist
chamber for 60 minutes. After rinsed with PBS for 2 min-
utes, the sections were incubated with the biotinylated
secondary antibody (Reagent B) for 10 minutes and
rinsed with PBS. The sections followed by incubation with
enzyme conjugate (Reagent C) for 10 minutes. Subse-
quently, the sections were stained with DAB and counter-
stained with hematoxylin. Serum blocking solution
(Reagent A) in place of the primary antibody was used as
a negative control. CK, EMA, NSE, Syn, and CgA showed
positive immunoreactivity in the cytoplasms of the cells.
TTF-1 showed positive immunoreactivity in the nuclei of
the cells. CD56 showed positive immunoreactivity in the
membranes of the cells.S-100 showed positive immuno-
reactivity in the nuclei and cytoplasms of the cells. Immu-
nostaining labeling intensities were defined as: +, less
than 10% of the positive tumor cells; ++, 10%–50% of the
positive tumor cells; +++ more than 50% of the positive
tumor cells; - negative labeling.
Statistical analysis was performed on relationship
between clinical parameters including gender, age, tumor
location, tumor size, and stage, 8 immunohistochemical
markers and patient prognosis by Two-Sample Kol-
mogorov-Smirnov Test using software of SPSS 10.0 (SPSS
Inc., Chicago, IL). Eighteen died cases of 21 patients with
SCC were used to compare with their clinicopathological
parameters. In these parameters, two groups each one was
divided for comparison, including gender: male and
female; age: ≤50 and >50 years old; tumor size: < 5 cm and
≥5 cm in diameter; tumor location: locations in upper
one-third or middle one-third and location in lower one-
third; stage: stages T1 or T2 and stages T3 or T4; immuno-
histochemistry data: positive labeling marked as + or ++
or +++ and negative labeling marked as - for each marker.BMC Cancer 2007, 7:38 http://www.biomedcentral.com/1471-2407/7/38
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The statistically significant difference was set P < 0.05
(two-sided probability).
Results
Clinical features
Between 1989 and 2005, twenty-one Chinese patients
were diagnosed with primary SCC, representing 0.05%
(21/4050) of all patients with esophageal malignancies
seen in our hospital. Clinicopathological data were sum-
marized in Table 1. The median age of the patients at the
time of diagnosis was 56 years, ranging from 30 to 76
years. Sixteen patients were men, with a male-to-female
ratio of 3.2:1. The most common initial symptoms were
dysphagia (18 cases, 85.7%) and retrosternal pain (3
cases, 14.3%). The duration of symptoms varied from 10
days to 9 months with a mean time of 2 months. The
tumors were located in the upper third of esophagus in 1
case, the middle third in 12 cases, and the lower third in 8
cases. Upper gastrointestinal barium examination showed
medullary morphology of the tumor in 18 out of 21 cases,
ulceration in 2 cases, and a mushroom-like appearance in
1 case. The mean tumor size was 5.8 cm long, ranging
from 1.2 cm to 15.5 cm.
Pathologic characteristics
Endoscopic biopsy results were available for 19 SCC
patients. Upon diagnosis, 5 patients presented with liver
metastasis, and 1 patient presented with thyroid gland
metastasis. Twelve patients underwent surgery, and lymph
node metastases were found in 8 cases, while 2 cases
showed SCC mixed with squamous cell carcinoma.
A total of 2 – 8 hematoxylin and eosin-stained sections
were examined for each patient. All tumors conformed to
2000 WHO histological criteria for small cell carcinoma
of the esophagus. Histological sections were referenced
using 2004 WHO histological criteria for pulmonary
small cell carcinoma, consisting of small, round, ovoid or
spindle-shaped cells with scant cytoplasm, ill-defined cell
borders, finely granular nuclear chromatin, and absent or
inconspicuous nucleoli (Figure 1). A nested or organoid
growth pattern was commonly seen, and peripheral pal-
isading of tumor cell nests was observed in most cases
(Figure 1A). Sheet-like growth was a dominant growth
pattern in 3 cases (Fig. 1B). In one case, morphology indi-
cated that lymphoma was present (Figure 1C). A total of
19 "homogenous" SCC cases and 2 cases with SCC mixed
with well-differentiated squamous cell carcinoma were
found (Figure 1D). In the 2 cases of SCC and squamous
cell carcinoma, no transitional lesion was found between
the two components.
Immunohistochemistry
Immunohistochemical study information was available
for all 21 cases and was shown in Table 2 and Figure 2.
Staining for eight immunological markers (CK, EMA,
NSE, Syn, CgA, CD56, TTF-1 and S-100) was performed
on all of the cases. Immunological reactivity of the sam-
ples was Syn 95.2%, CD56 76.2%, TTF-1 71.4%, NSE
61.9%, CgA 61.9%, CK 57.1%, EMA 61.9%, and S100
19.0%. In the two cases of combined squamous cell carci-
noma, the squamous cell carcinoma compartment
showed positive CK and EMA staining, but negative neu-
roendocrine marker staining. The small cell carcinoma
compartment showed positive neuroendocrine staining
and negative epithelial labeling (Figure 2).
Treatment
Nineteen patients underwent various treatments, includ-
ing resection, chemotherapy, radiotherapy and combined
therapy, summarized in Table 1. Of the 19 patients that
obtained treatment, 7 patients underwent treatment with
chemotherapy and surgery, 3 patients underwent chemo-
therapy and radiotherapy, 2 patients underwent resection,
chemotherapy and radiotherapy, 2 patients underwent
resection and radiotherapy, 2 patients underwent resec-
tion alone, 2 patients underwent chemotherapy alone,
and 1 patient underwent radiotherapy alone.
Follow-up
The median survival of the 21 patients was 18.3 months
after diagnosis. Follow-up information was summarized
in Table 1. Of the 19 patients that received treatment, the
median survival was 19.6 months, and the median sur-
vival of the 2 patients without anti-tumor treatment was 6
months. The longest survival time was 71 months, and the
shortest survival time was 3 months. The 2-year survival
rate was 28.6% (6/21) and the 5-year survival rate was
4.8% (1/21). Six patients died in 6 months (6/21, 28.6%),
9 patients died in one year (9/20, 45%) and 14 patients
died in two years (14/19, 73.7%).
Statistical analysis
The associations of survival time with gender, age, tumor
location, tumor size, TNM stage, and the 8 immunohisto-
chemical markers (CK, EMA, NSE, Syn, CgA, CD56, TTF-1
and S-100) were analyzed with nonparametric test
(Komolgorov-Smirnov method), and none of them was
statistically significant (P < 0.05, two-sided probability)'
[see Additional file 1]'.
Discussion
According to reports from different hospitals, esophageal
SCC was a rare disease [15-20]. The present proportion of
esophageal SCC at our Cancer Center was about 0.5% of
4010 cases of esophageal malignancies. The incidence of
esophageal SCC was much lower than the incidence of
invasive lung cancer SCC (15% to 25%) [21]. The clinical
features of the patients in this study were consistent with
other reports, and dysphagia was the most common pre-BMC Cancer 2007, 7:38 http://www.biomedcentral.com/1471-2407/7/38
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senting symptom in 86% of patients, lasted with 1~ 3
months prior to presentation [15]. The ratio of male-to-
female patients was 3.2:1, which is higher than the ratio
of 1.3:1 in previous reports [22]. The median age of the
patients in our study was 54 years old (ranging from 38 to
76 years old), which was lower than the median age of
63.8 years in one previous report [22], and close to the
median age of 58 years in another report [16].
Surgical pathological diagnosis for esophageal SCC was
not difficult. Microscopically, esophageal SCC was similar
to small cell lung cancer, consisting of round to spindle-
shaped cells with scanty cytoplasm, granular nuclei and
inconspicuous nucleoli [23-25]. Two cases of esophageal
SCC presented with squamous cell carcinoma. Several
previous articles reported combined esophageal SCC and
squamous cell carcinoma, and it was widely-believed that
the histological heterogeneity indicates origin from
multipotent reserve cells [26-29]. We did not find any
clinical significance related to the histological heterogene-
ity of the tumors.
Positive labeling with four neuroendocrine markers
including Syn, CD56, NSE and CgA was apparent in these
cases, which was similar to previous reports of esophageal
SCC [28,30] and pulmonary SCC [2]. None of the normal
squamous epithelium specimens or heterogeneous com-
ponents of squamous cell carcinoma showed positive
labeling. Thus, Syn, CD56, NSE and CgA were useful
markers for differential diagnosis of SCC arising in the
lung and the other organs. TTF-1 was a newly described
nuclear transcriptional factor expressed in epithelial cells
of thyroid and lung and in a high proportion of SCC. In
the present study, 71.4% of esophageal SCC cases were
positive for TTF-1, which was higher than the previously
reported rate [31]. We confirmed that TTF-1 showed
higher positive labeling in primary esophageal SCC, sug-
gesting that it was a suitable marker for diagnosis and dif-
ferentiation of esophageal SCC.
Treatment of esophageal SCC in the present study
included surgical resection, chemotherapy, radiotherapy,
and combinations of these treatments. We could derive
Table 1: Clinicopathological features of the 21 patients with SCC
Case No. Gender/Age Symptoms/duration (months) Mass location Gross Size (cm) TNM stage or 
metastasis
Therapy Follow-up 
(months/
status)
1 M/38 Progressive dysphagia/2 Middle 1/3 Medullary 4 PT3N0M0 S+C+R 48/DOD
2 F/62 progressive dysphagia/1 Middle 1/3 Medullary 3 PT2N1M0 IIb S+C+R 71/DOD
3 M/62 progressive dysphagia/3 Lower 1/3 Medullary 1.5 PT2N2M0 S 5/DOD
4 M/57 dysphagia/10 days Lower 1/3 Medullary 1.2 PT2N0M0 S+C 46/alive
5 M/51 dysphagia/1 Upper 1/3 mushroom-like 4 PT3N0M0 S+R 3/DOD
6 M/50 retrosternal complaint/9 Middle 1/3 Medullary 4 PT3N1M1 IV S+C 13/DOD
7 M/47 dysphagia/2 Middle 1/3 Medullary 10 PT2N0M0 S 3/DOD
8 M/43 progressive dysphagia/3 Lower 1/3 Medullary 7 T4N2M1 IV S+C 29/DOD
9 F/47 dysphagia/3 Middle 1/3 Medullary 4 PT3N1M0 II S+C 5/DOD
10 M/45 dysphagia/2 months Middle 1/3 Medullary 13 PT4N1M0 III S+C 3/DOD
11 M/68 dysphagia/1 Lower 1/3 Medullary 5 PT2N1M0 II S+C 15/DOD
12 F/52 dysphagia/2 Lower 1/3 Medullary 3 CT4N1M0 NT 7/DOD
13 M/46 progressive dysphagia/2 Lower 1/3 Medullary 15.5 liver 
metastasis
C1 2 / D O D
14 F/63 husk/2 and dysphagia/1 Middle 1/3 Medullary 5.5 thyroid 
metastasis
C 9/alive
15 M/57 Retrosternal complaint/1 Middle 1/3 Medullary 1.7 liver 
metastasis
C+R 15/DOD
16 F/76 progressive dysphagia/1 Middle 1/3 Medullary 6 NR NT 5/DOD
17 M/43 dysphagia and retrosternal 
pain/2
Middle 1/3 Medullary 3.5 PT3N1M0 S+R 32/DOD
18 M/76 dysphagia/1 Middle 1/3 Ulceration 5 NR R 28/DOD
19 M/73 Retrosternal complaint/3 Lower 1/3 Medullary 8 PT2N0M0 IIa C+R 15/DOD
20 M/70 Retrosternal complaint/4 Lower 1/3 Ulceration 9 NR C+R 13/alive
21 M/54 dysphagia/4 Middle 1/3 Medullary 8 PT3N1M0 C+R 8/DOD
NR, no record; NT, no treatment; S, Resection; C, Chemotherapy; R, Radiotherapy; DOD, Death of disease.BMC Cancer 2007, 7:38 http://www.biomedcentral.com/1471-2407/7/38
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no clear results as to the significance of adjuvant therapies.
However, the patients with the longest-term survival (48
and 71 months, respectively) received combination thera-
pies including surgical resection, chemotherapy, and radi-
otherapy. Due to the small number of cases in our study,
statistic analysis was not done. However, follow-up results
showed that patients receiving treatment had longer sur-
vival (median survival, 19.6 months) than those without
treatment (median survival, 6 months). Previous studies
reported that surgical resection with systemic chemother-
apy, radiotherapy, or combination therapy could produce
long-term remission and potential long-term survival in
esophageal SCC patients [16,20].
Previous studies from different hospitals showed very
poor prognosis for esophageal SCC patients. Investigators
at Memorial Hospital [20], Massachusetts General Hospi-
tal [17] and M.D. Anderson Cancer Center [16] reported
the median survival of esophageal SCC patients to be 7.5
months (range 1–21 months), 7 months (range, 3–17
months) and 12.5 months (range, 5–57 months), respec-
tively. In our study, the median survival was 18 months,
ranging from 3 to 71 months, and 28.6% of patients sur-
vived longer than 2 years.
The histogenesis of esophageal SCC may be APUD cells or
multipotent reserve cells [15,26]. In the present study,
observation of dual or multiple cell types, such as the
coexistence of squamous elements provides evidence of
derivation from multipotent reserve cells. Positive cytok-
eratin and neuroendocrine labeling supports the theory
that SCC arises from the lung, esophagus, and other
Hematoxylin and eosin-stained sections showing morphology of esophageal SCC morphology Figure 1
Hematoxylin and eosin-stained sections showing morphology of esophageal SCC morphology. Nested or organoid growth pat-
tern was the most common (A). Sheet-like growth was a dominant pattern in 3 cases (B). In one case, we observed marked 
cellularity similar to lymphoma (C). Combined SCC of the esophagus with well-differentiated squamous cell carcinoma (D). 
(Mag. × 400).BMC Cancer 2007, 7:38 http://www.biomedcentral.com/1471-2407/7/38
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organs that share histogenesis. Establishing a histogenetic
relationship among different organs requires further
study, but the current histological and immunological
results provide evidence of a common derivation.
Conclusion
In summary, Chinese esophageal SCC in the present study
is relatively rare and has similar histology to SCC that
arises in the lung compartment, and patients have a poor
prognosis. Higher percentages of positive labeling of Syn,
CD56, CgA, NSE, and TTF-1 in esophageal SCC cases
implicated that they are valuably applied in differential
diagnosis of the malignancy.
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Table 2: Immunohistochemical results of 21 SCC cases
Case No Pathology CK EMA NSE Syn CgA CD56 S-100 TTF-1
1 SCC ++ +++ +++ +++ ++ +++ - +++
2 SCC +++ ++ + ++ - + - -
3 SCC ++ +++ ++ +++ + +++ - ++
4 SCC +++ ++ ++ ++ ++ ++ ++ +++
5 SCC ++ +++ - + - +++ -
6 SCC ++ ++ + +++ ++ ++ - +++
7 SCC +++ ++ + ++ + +++ + ++
8 SCC +++ ++ +++ ++ - +++ - ++
9 SCC - - +++ +++ ++ +++ ++ +++
SqCC +++ ++ - - - - - -
10 SCC - + + +++ +++ - - ++
11 SCC - - - ++ - ++ - -
1 2 S C C --- + + ---+
13 SCC - - ++ +++ ++ +++ - -
14 SCC ++ - + +++ ++ ++ - +++
15 SCC + ++ - ++ ++ +++ - ++
16 SCC - - - ++ - - - ++
17 SCC ++ +++ ++ +++ + +++ + -
18 SCC - ++ - - ++ - - +++
19 SCC ++ ++ - ++ - +++ - -
20 SCC - - + +++ - ++ - ++
21 SCC - - - +++ +++ - - ++
SqCC +++ - - - - - - -
Total positive cases (%) 12(57.1) 13(61.9) 13(61.9) 20(95.2) 13(61.9) 16(76.2) 4(19.0) 15(71.4)
SCC, small cell carcinoma; SqCC, squamous cell carcinoma. +, less than 10% of the tumor cells were positive; ++, 10%–50% of the tumor cells were 
positive; +++, more than 50% the tumor cells were positive; -, negative labeling.BMC Cancer 2007, 7:38 http://www.biomedcentral.com/1471-2407/7/38
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